济南做尿酸检查挂什么科(济南痛风患处能放血治疗吗) (今日更新中)

BEIJING, Oct. 11 (Xinhuanet) -- An experimental drug that can remove amyloid plaques from the brains of Alzheimer's patients is being developed by Swiss Roche Holding AG in a small early-stage study, according to a report published in the Archives of Neurology on Monday.Researchers suspect the build-up of such plaques may be a cause of the memory robbing disease, although that theory has yet to be definitively proved. Gantenerumab, a biotech drug designed to bind to amyloid plaques in the brain and remove them, is being targeted at the early stages of Alzheimer's with the hope it can slow progression of the disease while patients are still able to function.The Phase I study of 16 Alzheimer's patients tested gantenerumab at two doses against a placebo over six months of treatment.The Roche drug led to a dose-dependent reduction of brain amyloid, while amyloid load increased in patients receiving a placebo, the report said.The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of the experimental drug that are well tolerated and safe, the report said.Much larger trials and further study will be needed to fully understand how gantenerumab works and whether it can stave off Alzheimer's, said the report.Roche is approaching the disease far earlier because amyloid accumulates for 15 years before dementi.

KUWAIT CITY, Nov. 27 (Xinhua) -- Two warships from China on Sunday docked at Kuwait's Shuwaikh port to start a five-day official visit to the Gulf Arab emirate.The tour by the destroyer "Wuhan" and the frigate "Yulin" marked the first visit by Chinese naval vessels to Kuwait since the two countries established diplomatic ties 40 years ago."This visit marks a historic occasion and Kuwaiti navy looks forward to future cooperation to improve the relationship and friendship between our two navies," said Colonel Khaled Ahmad Abdallah from Kuwait's navy.The flotilla was part of the ninth Chinese naval convoy to conclude its escort mission in the Gulf of Aden and waters off Somalia.Commander of the flotilla Guan Jianguo hopes the visit would enhance mutual cooperation between the two navies, which in turn would contribute to boosting bilateral relations.The flotilla would visit Oman after its stay in Kuwait.

BEIJING, Nov. 30 (Xinhua) -- China's efforts to fight AIDS are impressive and its experience can be shared, according to Michel Sidibe, executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS)."We have seen progress in terms of new infections. The number of people going into treatment is increasing and the mortality rate is going down very quickly in China," Sidibe said during an interview with Xinhua on Wednesday.Sidibe said he was impressed by the country's political leadership and commitment to controlling AIDS.According to UNAIDS, the country has reported a 60-percent reduction in deaths due to AIDS over the past eight years.New HIV infection cases in China have been reduced from 70,000 people annually in 2005 to around 48,000 in 2011, according to the country's health department."However, China's success will not only be measured by what it has done for the Chinese people," Sidibe said.China has successful experience in reducing new HIV infections among intravenous drug users, which can be shared with the rest of the world, particularly east Europe and south Asia where HIV infections among drug abusers is a major challenge, he said.Sidibe suggested that the country should work with the rest of the developing world, particularly Africa, in fighting AIDS.A partnership between China and Africa will make a "big, big difference" in reducing AIDS mortality rates and introducing new technology and perspectives in Africa, said the official who had worked for UN in several African countries for more than two decades.Admitting the challenges of funding AIDS control programs during the current global economic downturn, Sidibe called for global solidarity and increasing shared responsibilities among countries."It is a critical moment now. It is not a time to stop investment but to redouble our efforts, to make sure that we will continue to make progress in the fight against HIV," Sidibe said."Getting to Zero" has been chosen as the main theme of World AIDS Day for the next five years, referring to UNAIDS' vision of "zero new HIV infections, zero discrimination and zero AIDS-related deaths."Sidibe met with Li Congjun, president of the Xinhua News Agency, on Wednesday before the interview. The agency has launched a global media campaign in cooperation with UNAIDS to raise public awareness about HIV/AIDS."The partnership (with Xinhua) is not only about writing news about HIV. It is about helping people to change their attitude and make decisions to help protect themselves," Sidibe said.

LAS VEGAS, the United States, Jan. 12 (Xinhua) -- NVIDIA, the computer chip manufacturer best known for its high performance graphics processors, is looking to make further inroads with the automobile industry by integrating its new Tegra 3 mobile processors in upcoming vehicle models.At the 2012 International Consumer Electronics Show (CES), NVIDIA and Audi announced that all models from the German auto manufacturer in 2013 will use Tegra 3 quad-core processors to power their in-car digital systems.These processors, which are traditionally found in smartphones and tablets, will support the vehicle's digital systems at lower energy rates and also allow for shorter lead times in getting concepts to market.In addition to powering infotainment systems that allow for web browsing and Google Earth integrations, they will also give automakers the ability to replace traditional dashboards with instrument cluster systems, or digital dashboards."By leveraging technology from the very latest smartphones and tablets, Audi is leading the market with innovations that enhance safety and make driving more enjoyable," said Ricky Hudi, the company's chief executive engineer, at Audi's official conference at CES.For Audi, this means that they will be able to offer cars like the next-generation A3 model beginning in 2013, which features an integrated touchpad system and mounted monitor with the ability to render 3D imaging. Current 2012 Audi vehicles house the Tegra 2 processor."It's a natural progression with people getting so accustomed to mobile and expecting it from your automobiles as well. Partnering really closely with automotive OEMs enable us to help them realize the driver experience they're looking to deliver," said Phillip Hughes, NVIDIA's director of automotive sales and business development, in an interview with Xinhua.In addition to Audi, Tesla and Lamborghini will also be including the newest NVIDIA Tegra 3 processor in upcoming models. At this year's CES, Lamborghini is showcasing the Lamborghini Aventador, a nearly 700 horsepower vehicle with the capability of going from 0 to 60 miles per mile in less than five seconds."NVIDIA technology is enabling us to do more with our vehicles and gives our cars the ability to have the technology you'd expect from a car like this," said Kelly Snyder, an event manager with Lamborghini, to Xinhua. The retail price point for the Lamborghini Aventador starts at 382,000 U.S. dollars.More than just powering the car's digital experiences, however, integrating NVIDIA's processors will help the auto manufacturer build better cars by reducing the power to weight ratio that is a key consideration in manufacturing higher performing cars."By moving elements like the odometer to a digital dashboard platform, it reduces the power to weight ratio that is so critical to the design and manufacturing of automobiles like the Lamborghini," explained Snyder.NVIDIA also expects that the integration of these processors will bring the development cycle of the automotive industry up to speed with the consumer electronics industry through Virtual Computing Modules (VCMs) powered by the Tegra 3. These VCMs allow auto manufacturers to quickly prototype and ship consumer technology innovations to automobiles, reducing a development lifecycle that once took seven years, to roughly a year."At the end of the day, our goal is to help automotive OEMs bridge the gap between OEM and consumer technology," said Hughes.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.

来源：资阳报